Table 2.
Treatment response regarding combined antimalarial treatment, Colombia
Response | CQ and SP* | AQ and SP | MQ and SP | AS and SP | AS and AQ | AS and MQ | AS, MQ, and PQ |
---|---|---|---|---|---|---|---|
ETF, no. (%) | 1 (1.6) | 1 (1.1) | 0 | 0 | 0 | 0 | 0 |
LCF, no. (%) | 10 (15.6) | 1 (1.1) | 0 | 0 | 0 | 0 | 0 |
LPF, no. (%) | 0 | 0 | 1 (1.1) | 2 (2.0) | 0 | 0 | 0 |
SCPR, no. (%) | 53 (82.8) | 89 (97.8) | 91 (98.9) | 96 (98.0) | 52 (100) | 25 (100) | 25 (100) |
Total | 64 | 91 | 92 | 98 | 52 | 25 | 25 |
CQ = chloroquine; SP = sulfadoxine-pyrimethamine; AQ = amodiaquine; MQ = mefloquine; AS = artesunate; PQ = primaquine; ETF = early therapeutic failure; LCF = late clinical failure; LPF = late parasitologic failure; SCPR = suitable clinical and parasitologic response.